首页> 外文会议>Proceedings of the 3rd Congress of the Asian Pig Veterinary Society >The efficacy trial of Enterisol(R) Ileitis by drinking water in a commercial swine farm
【24h】

The efficacy trial of Enterisol(R) Ileitis by drinking water in a commercial swine farm

机译:在一家商业猪场喝水回肠肠炎的功效试验

获取原文

摘要

Porcine proliferative enteropathy(PPE), often called ileitis, is a common disease affecting the intestine of pigs. It is caused by bacterium Lawsonia intracellularis and transmitted through oral-faecal contact, and the farms suffer economic losses to the infection. Enterisol(R) Ileitis is a bacterium attenuated live oral vaccine developed by Boehringer-Ingelheim animal health, it has being sold in 19 European countries, North America, Australia and Philippines, and it provides an innovative health management method for the farm managers and veterinarians. The purpose of this study was to evaluate the efficacy of vaccination of Enterisol(R) Ileitis by drinking water method on the ileitis prevention and control and its economic benefits. Before the start of the trial, it was confirmed by veterinary experts through clinical observation, post-mortem necropsy and serological examination that clinical and sub-clinical ileitis affecting this farm. Six batches of a total of 4680 pigs were allocated into three experiment groups (with a start number of 890, 690, 802 pigs, respectively ) and three control groups(start with number of 787, 743, 768 pigs).The experiment groups were vaccinated with Enterisol(R) Ileitis at 3 weeks, 7 weeks and 9 weeks, respectively. The same management programs were adopted to both the experiment groups and the control. The bloody diarrhea feces,black soft feces, culling rate, mortality, ADG of growing pigs, average fattening days and FCR and pass rate for export of the experiment groups and the control were recorded, computed and compared. Results showed that the rate of pigs showing bloody diarrhea feces of the experiment and control were 0.37%,0.44%,0.07% reduction was observed. Other parameters like occurrence rate of black soft feces (6.76% experiment VS 15.26% control) , culling rate (3.08% VS 8.59%) , mortality (0.4% VS 1.79%) , ADG of growing pigs (733.8g VS 639.3g) , average fattening days ( 105 VS 114) and FCR (2.57 VS 2.74) and pass rate for export (96.54% VS 89.63%). All the results lead to the conclusion that using Enterisol(R) Ileitis can solve the problems of infection of ileitis, improve the farm performance and gain more economic benefits.
机译:猪增生性肠病(PPE),通常称为回肠炎,是一种影响猪肠的常见疾病。它是由细胞内劳森菌(Lawsonia intracellularis)引起的,并通过粪便与粪便的接触而传播,养殖场因此遭受了经济损失。 Enterisol(R)回肠炎是由勃林格殷格翰动物保健公司开发的一种减毒活口服疫苗,已在19个欧洲国家,北美,澳大利亚和菲律宾销售,它为农场经理和兽医提供了一种创新的健康管理方法。这项研究的目的是评估通过饮用水方法接种Enterisol®回肠炎对预防和控制回肠炎的功效及其经济效益。在试验开始之前,兽医专家已通过临床观察,验尸尸检和血清学检查证实,该农场受到临床和亚临床回肠炎的影响。将总共​​6680头猪中的6批次分为三个实验组(起始数量分别为890、690、802猪)和三个对照组(起始数量分别为787、743、768猪)。分别在3周,7周和9周时接种Enterisol®回肠炎疫苗。实验组和对照组均采用相同的管理程序。记录,计算和比较血性腹泻粪便,黑色粪便,淘汰率,死亡率,生长猪的平均日增重,平均育肥天数和FCR以及实验组和对照组的出口通过率。结果表明,实验组和对照组的猪出现腹泻血样的比例分别为0.37%,0.44%,0.07%。其他参数包括黑色软便的发生率(实验的6.76 VS对照的15.26%),剔除率(3.08%的VS 8.59%),死亡率(0.4%的VS 1.79%),生长猪的日增重(733.8g VS 639.3g),平均育肥天数(105 VS 114)和FCR(2.57 VS 2.74)和出口合格率(96.54%VS 89.63%)。所有结果都得出结论,使用Enterisol(R)回肠炎可以解决回肠炎的感染问题,改善农场经营状况并获得更多的经济效益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号